Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Vercise Deep Brain Stimulation System

Boston Scientific news release; 2017 Dec 11

Boston Scientific Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Vercise Deep Brain Stimulation (DBS) System. DBS is used to treat the symptoms of Parkinson disease (PD), a degenerative condition that affects more than 1 million people in the US and 10 million worldwide. DBS works by stimulating a targeted region of the brain through implanted leads that are powered by a device called an implantable pulse generator (IPG). The approval was based on the INTREPID study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for PD in the US. The INTREPID study evaluated the safety of the system in 292 patients at 23 sites and also evaluated its effectiveness.

Boston Scientific is headquartered in Marlborough, MA.


Boston Scientific receives US FDA approval for the Vercise™ Deep Brain Stimulation System. Platform offers physicians advanced technology to treat symptoms of Parkinson's disease. [news release]. Marlborough, MA: Boston Scientific Corporation. December 11, 2017. Accessed January 2, 2018.

This Week's Must Reads

Body Image Dissatisfaction in Patients with MS, Int J MS Care; ePub 2018 Nov 1; Stevens, et al

Unemployment Linked with Stigma in MS, Int J MS Care; ePub 2018 Nov 1; Hategeka, et al

Total Hip, Knee Arthroplasty in Patients with MS, Int J MS Care; 2018 Sep-Oct; Gutman, et al

Intracerebral Hemorrhage in Multiple Sclerosis, J Stroke Cerebrovasc Dis; ePub 2018 Oct 29; Zulfiger, et al

Assessment of CAT Version of Neuro-QOL for MS, Mult Scler; ePub 2018 Nov 1; Healy, et al

Must Reads in FDA Actions

FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3